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Identification of the Mutations in the Prostaglandin Transporter 
Gene, SLCO2A1 and Clinical Characterization in Korean Patients 
with Pachydermoperiostosis
Pachydermoperiostosis (PDP), or primary hypertrophic osteoarthropathy, is a rare genetic 
disease affecting both skin and bones. Both autosomal dominant with incomplete 
penetrance and recessive inheritance of PDP have been previously confirmed. Recently, 
hydroxyprostaglandin dehydrogenase (HPGD) and solute carrier organic anion transporter 
family member 2A1 (SLCO2A1) were reported as pathogenic genes responsible for PDP. 
Both genes are involved in prostaglandin E2 (PGE2) degradation. We aimed to identify 
responsible genes for PDP and the clinical features in Korean patients with PDP. Six 
affected individuals and their available healthy family members from three unrelated 
Korean families with PDP were studied. All of the patients displayed complete phenotypes 
of PDP with finger clubbing, pachydermia, and periostosis. Mutation analysis revealed a 
novel heterozygous mutation in the SLCO2A1 gene at nucleotide 302 causing a 
substitution of the amino acid isoleucine to serine at codon 101 (p.IIe101Ser) in affected 
individuals. We also identified known SLCO2A1 mutations, one homozygous for 
c.940+1G>A, and another compound heterozygous for c.940+1G>A and c.1807C>T 
(p.Arg603*) from two PDP families. Genetic analyses of the PDP patients showed no 
abnormality in the HPGD gene. Our study further supports the role of mutations in the 
SLCO2A1 gene in the pathogenesis of PDP and could provide additional clues to the 
genotype-phenotype relations of PDP.
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INTRODUCTION
Pachydermoperiostosis (PDP), or primary hypertrophic osteo-
arthropathy, is a cluster of genetic syndromes characterized by 
three major symptoms; digital clubbing, periostosis, and pachy-
dermia. Additional manifestations including excessive sweat-
ing, acne, arthropathy, and acro-osteolysis of long bones have 
been reported (1). The phenotypic spectrum of PDP is broad, 
and three clinical presentations of PDP are generally recognized: 
the complete form involving all three major symptoms, the in-
complete form with periostosis without pachydermia, and the 
‘forme fruste’ with pachydermia and minimal or no skeletal 
anomalies (2).
 Both autosomal dominant with incomplete penetrance and 
recessive inheritance have been suggested in PDP (3). The pre-
cise incidence and prevalence are still unknown. Uppal et al. (4) 
recently discovered homozygous mutations in the hydroxypros-
taglandin dehydrogenase (HPGD) gene in a subset of patients 
with PDP. In addition, exome analysis of PDP in Japanese, Chi-
nese, Caucasian, and other races has revealed homozygous 
and compound heterozygous mutations in the solute carrier 
organic anion transporter family member 2A1 (SLCO2A1) gene 
(5-8). Both HPGD and SLCO2A1 genes are involved in prosta-
glandin E2 (PGE2) degradation. Increased levels of PGE2 in pa-
tients with causal genetic mutations could contribute to the 
pathogenesis of PDP (9).
 To date, one family of PDP related to SLCO2A1 gene muta-
tion has been reported in Korea (10). In this study, we describe 
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complete types of PDP carrying SLCO2A1 mutations including 
a novel mutation in Koreans with review of literature. 
MATERIALS AND METHODS
Subjects
All participants were of Korean ethnicity. Six patients with PDP 
and their family members from three unrelated families were 
recruited. 
Family 1 
The case of this family (Fig. 1 and 2A-C) has been previously re-
ported (11). The 56-year-old proband, who was born to healthy 
non-consanguineous parents, visited the clinic for genetic coun-
seling of his son. At 19 years of age, the proband presented with 
enlarged hands and feet, knee joints swelling and pain and was 
then referred to a neurosurgeon for suspicion of acromegaly. 
He underwent hypophysectomy, which showed no tumor le-
sion in the specimen. Attention was aroused only after perios-
Fig. 1. Pedigrees of affected individuals with SLCO2A1 mutations. In the pedigree, 
arrows indicate the proband. Filled black, patients with PDP; Half-black, healthy 
members with a heterozygous mutation; Gray, healthy members not doing genotyping 
test. 
Family 1
F1-P1 F1-P2 F1-P3
Family 2 Family 3
F2-P4 F3-P5 F3-P6
Fig. 2. Clinical features of affected individuals with SLCO2A1 mutations. (A-C) Clinical pictures of family 1 proband. (A) Thickening and furrowing of the facial skin. (B-C) Digital 
clubbing and swelling of the ankle joint. (D-H) Clinical pictures of family 2 proband. (D) Thickening and greasiness of facial skin. (E) Digital clubbing. (F-G) Cortical hyperostosis 
of long bones. (H) Diffusely increased uptake in the whole axial and appendicular long bones shown by whole body bone scan. (I-J) 18F-fluoride PET scan images of femur and 
tibia show increased cortical/periosteal uptake in the proband of family 3.
A
F G H I J
B C D E
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teal thickening was observed in the skeletal survey of the hands 
and forearm bones, indicating primary hypertrophic osteoar-
thropathy as well as facial furrowing. His two brothers, who were 
also diagnosed as PDP, showed similar clinical features to the 
proband.
Family 2
The 19-year-old proband (Fig. 1 and 2D-H) was born to a healthy 
non-consanguineous couple. Beginning at 17 years of age, he 
noticed inappropriately thickened lower legs and swelling of 
ankle joints. He also complained of hyperhidrosis, acne, and 
difficulty of squatting. He had atrial septal defect (ASD), patent 
ductus arteriosus (PDA), and valvular heart disease and under-
went an operation for PDA at the age of 1 month. A physical ex-
amination revealed enlargement of the terminal phalanges and 
facial furrowing. Skeletal survey showed periosteal thickening of 
the long bones. The radionuclide whole body bone scan (WBBS) 
showed diffusely increased uptake in the whole axial and ap-
pendicular long bones, suspicious of metabolic bone disease. 
Results of laboratory analyses, including growth hormone, in-
sulin-like growth factor 1, and thyroid-stimulating hormone 
were normal. His parents were not clinically affected.
Family 3
The case of this family was recently reported during preparation 
of this manuscript (10). Two siblings (Fig. 1) of ages 23 and 19 
years presented with progressive pachydermia and enlargement 
of their hands and feet since puberty. They also complained of 
hyperhidrosis, acne, and frontal furrowing. The brothers suffer-
ed from watery diarrhea; however, colonoscopic finding was 
not remarkable. The younger patient had a history of the opera-
tion for PDA in infancy; whereas his older brother had no histo-
ry of PDA or other congenital heart diseases. Skeletal survey 
showed periosteal thickening of the long bones. The 18F-fluo-
ride positron emission tomography (PET) scan showed incre-
ased cortical/periosteal uptake of long bones (Fig. 2I and J). La-
boratory tests including growth hormone and insulin-like growth 
factor 1 were within normal limits. Their parents were healthy 
without any similar features.
Mutation analysis of the associated genes
A mutation analysis of the affected individuals and their family 
members was performed by direct sequencing of PCR products 
amplified from genomic DNA. Genomic DNA was extracted 
from peripheral blood leukocytes using conventional methods. 
The DNA sequences of SLCO2A1 and HPGD were obtained from 
the available online database (NM_005630.2 and NM_000860.4, 
respectively). Primers were designed using Primer 3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/). All exons and their 
exon-intron boundaries in SLCO2A1 and HPGD were ampli-
fied via PCR. Direct sequencing was performed using the Big-
DyeTM Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Waltham, MA, USA).
Ethics statement
The study was approved by the institutional review board (IRB) 
Table 1. Clinical phenotypes of Korean patients with pachydermoperisostasis
Phenotypes
Cases
F1-P1 F1-P2 F1-P3 F2-P4
F3-P5
Kim et al. (10)
F3-P6
Kim et al. (10)
Current age, yr 56 54 52 19 23 19
Onset age, yr 19 17 20 17 puberty 13
Gender M M M M M M
SLCO2A1 mutations c.302T>G c.302T>G c.302T>G c.940+1G>A
c.1807C>T
c.940+1G>A
c.940+1G>A
c.940+1G>A
c.940+1G>A
Triad
   Digital clubbing
   Periostosis
   Pachydermia
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Skin
   Palmar and plantar hyperhidrosis
   Acne
   Seborrhoea and eczema
+
+
+
-
+
+
-
+
+
-
+
+
-
+
+
-
+
+
Skeletal
   History of bone fractures
   Swelling of large joints
   Painful joints on exercise
   Hydrarthrosis
-
+
+
+
-
+
+
+
-
+
+
+
-
+
+
+
-
+
+
+
-
+
+
+
Others
   Anemia
   Hypoalbuminemia
   Patent ductus arteriosus
-
-
-
-
-
-
-
-
-
-
-
+
-
-
-
-
-
+
M, male; +, positive; -, negative or unknown.
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Fig. 3. Localization and sequence chromatogram of identified SLCO2A1 mutations. Upper: The positions of the mutations in the exons of SLCO2A1 in this study. Lower: SL-
CO2A1 mutations in PDP families. family 1, (A) c.302T>G; family 2, (B) c.940+1G>A and (C) c.1807C>T; family 3, (C) c.940+1G>A.
SLCO2A1, Chromosome 3q21
exon
c.302T>G c.940+1G>A
1 2 3 4 5 6 7 8 9 10 11 12 13 14
c.1807C>T
c.302T>G (p.Ile101Ser) c.940+1G>A (p.R288Gfs*7) c.1807C>T (p.R603*)
A B C
of Gachon University Gil Medical Center, Korea (IRB No. GIR-
BA2151). Informed consent was obtained from all subjects be-
fore participation.
RESULTS
Clinical features of PDP patients
Based on major diagnostic criteria (digital clubbing, periostosis, 
and pachydermia) (1), all patients showed major clinical find-
ings and conformed to the diagnosis of PDP. They were catego-
rized as having the complete form and developed major symp-
toms before the age of 20 years and subsequently suffered from 
progressive skin thickening with seborrhea, swelling of periar-
ticular tissue, and joint discomfort or arthralgia. Their parents 
did not show clinical signs of PDP. The clinical phenotypes of 
PDP patients are summarized in Table 1.
Identification of SLCO2A1 as a gene responsible for PDP
PCR was performed for screening of SLCO2A1 and HPGD mu-
tations followed by a direct sequence analysis, and no HPGD 
mutation was found in affected individuals. The results of these 
genetic analyses are shown in Fig. 3.
 In family 1, DNA sequencing of the proband revealed a novel 
heterozygous mutation in the SLCO2A1 gene at nucleotide 302 
(c.302T>G) causing a substitution of the amino acid isoleucine 
(Ile) to serine (Ser) at codon 101 (p.Ile101Ser) in exon 3 as well 
as a known polymorphism (A396T) in exon 14. The two broth-
ers of the proband were also heterozygous for c.302T>G. The 
proband’s son, who seemed normal in appearance, did not car-
ry the mutations.
 In family 2, the proband showed compound heterozygous for 
2 different SLCO2A1 mutations; c.940+1G>A and c.1807C>T. 
The c.940+1G>A mutation was located in the splice donor site 
of intron 7, which resulted in the loss of exon 7 and a truncation 
of prostaglandin transporter (5,12), and c.1807C>T in exon 13 
introduced a stop codon at position 603 (p.Arg603*). The pati-
ents’ father and mother were heterozygous for c.940+1G>A and 
c.1807C>T, respectively. In family 3, the brothers were homozy-
gous for c.940+1G>A. The patients’ father was heterozygous for 
c.940+1G>A, and evaluation of the mother was not available. 
DISCUSSION
PDP or primary hypertrophic osteoarthropathy is characterized 
by pachydermia, periostosis and finger clubbing; however, the 
phenotypic spectrum of PDP is known to be broad (1). The di-
agnosis of PDP is based on the typical clinical features and ra-
diological data. PDP needs to be differentiated from acromega-
ly and secondary hypertrophic osteoarthropathy that is associ-
ated with pulmonary or cardiac disease. For the differential di-
agnosis, hormone tests including growth hormone and thyroid 
stimulating hormone, absence or presence of thickening and 
furrowing of facial skin, and sella turcica imaging might be help-
ful (13).
 Since PDP was first described in 1868 (1), mutations in HPGD 
and SLCO2A1 have been identified in families affected with PDP 
(4-6). So far, 43 different SLCO2A1 mutations have been report-
ed and are summarized in Table 2. Our study identified a novel 
mutation, c.302T>G, as well as known mutations, c.940+1G>A 
and c.1807C>T, in the SLCO2A1 gene. The c.940+1G>A muta-
tion was suggested as a hot spot in both Chinese Han and Euro-
pean Caucasian patients with PDP (3,6,14). Sasaki et al. (5) in-
sisted that the c.940+1G>A mutation is a major mutation as an 
ancient founder allele in Japanese PDP patient. Considering 
ethnic roots and regional proximity, the c.940+1G>A mutation 
might also be a common mutation detected in Korean PDP pa-
tients. 
 A considerable number of PDP patients showed autosomal 
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recessive transmission. However, autosomal dominant trans-
mission with incomplete penetrance has been also reported in 
previous studies (3). In this study, three patients of family 1 car-
ried a heterozygous c.302T>G mutation. The mutated alleles 
supposed to be autosomal dominant inheritance were c.302T>G, 
c.754C>T, c.830_831insT, c.861+2T>G, c.1065dupA, and c.1333C 
>T (3,7,8). The patients having c.754C>T and c.830_831insT al-
leles showed mild clinical symptoms, whereas PDP patients 
Table 2. Summary of the genetic SLCO2A1 mutations in patients with pachydermoperisostasis in the literature
References Mutation Origin Sex Age Clubbing
Periosto-
sis
Pachy-
dermia
Hyperhi-
drosis
Sebor-
rhea
Arthral-
gia
Zhang et al. (19) c.940+1G>A c.1602C>A Chinese M 22 + + + + NA +
Zhang et al. (3) c.855delA
c.855delA
c.855delA
c.1106G>A
c.1393G>A
c.493G>T
c.664G>A
c.861+2T>C
c.1065dupA
c.855delA
c.855delA
c.855delA
c.1106G>A
c.1393G>A
c.1136G>A
c.1634delA
Chinese
Chinese
Chinese
Chinese
Chinese
Chinese
Chinese
Chinese
Chinese
M
F
F
M
M
M
M
M
M
36
47
42
23
26
18
24
42
17
+
-
-
+
+
+
+
+
+
+
-
-
+
+
+
+
+
+
+
-
-
+
+
+
+
+
+
-
-
-
+
-
-
-
-
+
+
-
-
+
+
+
+
+
+
+
-
-
+
+
+
+
+
+
Zhang et al. (31) c.235-1G>T c.656C>T Chinese M 27 + + + + NA +
Zhang et al. (6) c.97-1G>A
c.764G>A
c.664G>A
c.97-1G>A
c.1634delA
c.940+1G>A
Chinese
Chinese
Chinese
M
M
M
24
27
21
+
+
+
+
+
+
+
+
+
NA
NA
NA
NA
NA
NA
NA
NA
NA
Cheng et al. (32) c.547G>A
c.940+1G>A
c.1807C>T
c.1602C>A
Chinese
Chinese
M
M
25
37
+
+
+
+
+
+
+
NA
+
+
+
+
Niizeki et al. (12) c.940+1G>A
c.754C>T
c.421G>T
c.940+1G>A
c.1279_1290del12
c.1807C>T
c.940+1G>A
c.1807C>T
Japanese
Japanese
Japanese
Japanese
M
M
M
M
19
21
20
20
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-
+
-
+
+
-
+
-
+
Sasaki et al. (5) c.940+1G>A
c.310G>A
c.940+1G>A
c.940+1G>A
c.1279_1290del12
c.1040C>T
c.940+1G>A
c.1668G>C
Japanese
Japanese
Japanese
Japanese
M
M
M
M
24
25
45
53
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-
-
+
+
+
-
+
+
-
+
Niizeki et al. (9) c.1279G>A c.1807C>T Japanese F 67 + + - - - +
Minakawa et al. (33) c.940+1G>A c.1279_1290del12 Japanese M 15 + + + + + +
Busch et al. (14) c.940+1G>A
c.940+1G>A
c.940+1G>A
c.1292delC
c.763G>A
c.763G>A
c.1668G>C
c.940+1G>A
c.940+1G>A
c.1292delC
c.763G>A
c.763G>A
Japanese
Japanese
Japanese
Indian
Indian
Indian
M
M
M
M
M
M
53
21
19
27
26
28
+
+
+
+
+
+
+
NA
NA
NA
+
+
NA
+
+
+
NA
NA
NA
NA
NA
NA
+
+
NA
NA
NA
+
NA
NA
+
NA
NA
+
+
+
Seifert et al. (8) c.830_831insT
c.830_831insT
c.830_831insT
c.830_831insT
c.1670T>C
c.754C>T
c.830_831insT
c.830_831insT
c.830_831insT
c.1670T>C
Turkish
Turkish
Turkish
Turkish
Iraq
Dutch
M
M
M
M
M
M
21
19
7
40
38
28
+
+
-
+
+
+
+
+
-
-
+
-
+
+
-
-
+
-
+
+
-
-
+
-
+
+
-
-
+
-
+
+
-
-
+
-
Diggle et al. (7) c.1259G>T
c.941-1G>A
c.542G>C
c.1333C>T
c.290G>A
c.664G>A 
c.253A>T 
c.1105+4A>G
c.838C>T
c.310G>T
c.724+1G>T
c.542G>A
c.611C>T
c.1259G>T
c.1517C>A
c.542G>C
c.940+2T>A
c.664G>A
c.253A>T
c.1105+4A>G
c.1693T>G
c.310G>T
c.724+1G>T
c.542G>A
c.611C>T
Hispanic (Colombia)
Chinese
Turkish
Dutch
French
North African
North African
Dutch
Kabardin (Caucasus)
Italian
Algerian
Turkish
Italian
M
M
M
M
M
M
M
M
M
M
M
M
M
45
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
+
+
+
+
NA
NA
NA
NA
NA
NA
NA
NA
NA
+
+
+
+
NA
NA
NA
NA
NA
NA
NA
NA
NA
+
+
+
+
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Ayoub et al. (34) c.1016C>T c.1016C>T Saudi M 23 + + + + + +
Madruga Dias et al. (35) c.940+1G>A c.940+1G>A African M 26 + + + NA NA +
Saadeh et al. (36) c.838C>T
c.838C>T
c.838C>T
c.838C>T
Lebanese
Lebanese
M
M
22
24
+
+
+
NA
+
+
NA
NA
NA
NA
+
+
NA, unknown or not available.
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carrying c.302T>G, c.861+2T>G, c.1065dupA, and c.1333C>T al-
leles presented the full-blown phenotype (Table 2). We found 
no consistent clinical features or genetically unique character-
istics among those mutations.
 Males were more commonly and severely affected with the 
ratio of male:female of 9:1 (13). A few females carrying the SL-
CO2A1 mutation were not clinically affected or showed atypical 
phenotype of PDP (3,7,9). A simple explanation of the skewed 
sex ratio is lacking. Plausible assumptions were testosterone 
promoting disease expression, weaker reactivity to prostaglan-
din in women than men, and suppressed effects of estrogen on 
interleukin 1b-mediated induction of the COX-2 pathway in 
vessels (1,15,16).
 Besides typical skin and bone manifestations, accompanying 
PDA was reported in about one third of cases in PDP patients 
with HPGD mutation (17). However, congenital cardiac anom-
aly has scarcely been reported in SLCO2A1-mutated patients. 
Only one Dutch patient carrying c.1333C>T mutation in the SL-
CO2A1 gene was reported to have ASD (7). Prostaglandin trans-
porter–deficient mice by targeted deletion of the SLCO2A1 gene 
die as neonates probably as a result of a closure defect of the 
ductus arteriosus (18). Seifert et al. (8) reported that PDP pa-
tients with SLCO2A1 mutations did not show failure of postna-
tal ductus arteriosus closure. Contrary to previous reports, our 
patient carrying compound SLCO2A1 heterozygous mutations 
was diagnosed with congenital heart defects including ASD, 
PDA, and valvular heart disease. It is uncertain whether this 
case is a coincidental finding; or PDA might be a rare, fatal con-
dition in SLCO2A1-mutated PDP patients. 
 Both HPGD and SLCO2A1 genes are known to involve PGE2 
metabolism. Mutations in SLCO2A1 cause increased levels of 
PGE2 due to the failure of extracellular uptake of PGE2 (19,20). 
Urinary excretion of the main PGE2 metabolite, PGE-M, is the 
best measure of total endogenous PGE2 production in normal 
condition (21). Previous studies showed elevated urinary excre-
tion of PGE2 and PGE-M in PDP patients, suggesting that mea-
surement of urinary PGE2 and PGE-M can be helpful in early 
and differential diagnosis of PDP (3,4,12). Urinary PGE2 and 
PGE-M levels were not determined in the current study and fur-
ther measurement is needed.
 Increased prostaglandins, which have a biphasic role in bone 
metabolism, stimulate both bone resorption and formation (22). 
An increase in bone turnover markers was observed in young 
PDP patients who might have high disease activity (23,24). Pre-
viously, bone scintigraphy confirmed a high activity of bone 
turnover in the affected joints of PDP patients (25). Three-phase 
skeletal scintigraphy in a PDP patient detected increased tracer 
uptake around long bones, which indicated the active form of 
the disease (26). Our patient in family 2 also showed similar 
finding of increased radionuclide uptake along the long bone 
cortices by WBBS (Fig. 2H). In this study, 18F-fluoride PET scan 
was performed in PDP patients for the first time. PET scan also 
provided convincing evidence of hypermetabolic status in vari-
ous long bones. 
 There is no specific treatment for PDP (27). Clubbing is usu-
ally asymptomatic and does not require treatment (13). For pa-
tients with painful osteoarthropathy, the therapeutic options 
consist of salicylates, non-steroidal anti-inflammatory drugs, 
systemic corticosteroids and colchicine (27). Bisphosphonates 
or infliximab have been attempted in cases of PDP refractory to 
conventional therapy (28,29). Cosmetic surgery or botulinum 
toxin injections have been introduced for correcting rough fa-
cial features (13,30).
 We report on three unrelated PDP families and identified three 
different mutations in the SLCO2A1 gene, of which c.302T>G in 
exon 3 is novel. As with Japanese and Chinese studies, we deter-
mine that c.940+1G>A is a major mutation in Korean PDP pa-
tients. Although our study did not contain PG-related metabolic 
activity, we further support the role of mutations in the SL-
CO2A1 gene in the pathogenesis of PDP.
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